The ANeED study – ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial

BACKGROUND: Currently, there are no disease-modifying pharmacological treatment options for dementia with Lewy bodies (DLB). The hallmark of DLB is pathological alpha-synuclein (aS) deposition. There are growing amounts of data suggesting that reduced aS clearance is caused by failure in endolysosom...

Descripción completa

Detalles Bibliográficos
Autores principales: Chwiszczuk, Luiza Jadwiga, Breitve, Monica Haraldseid, Kirsebom, Bjørn-Eivind Bordewick, Selnes, Per, Fløvig, John Chr., Knapskog, Anne-Brita, Skogseth, Ragnhild E., Hubbers, Jessica, Holst-Larsen, Elin, Rongve, Arvid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Aging Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250712/
https://www.ncbi.nlm.nih.gov/pubmed/37304077
http://dx.doi.org/10.3389/fnagi.2023.1163184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250712/
https://www.ncbi.nlm.nih.gov/pubmed/37304077
http://dx.doi.org/10.3389/fnagi.2023.1163184

Ejemplares similares